<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77079">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102100</url>
  </required_header>
  <id_info>
    <org_study_id>1309012678</org_study_id>
    <nct_id>NCT02102100</nct_id>
  </id_info>
  <brief_title>The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users</brief_title>
  <official_title>Menthol's Effects on Nicotine Reinforcement in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help determine if menthol administered by inhalation via electronic
      cigarettes (e-cigarette) changes the reinforcing effects of pure nicotine administered
      intravenously in cigarette smokers who smoke mentholated or non-mentholated cigarettes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Menthol's Effects on Nicotine Reinforcement in Smokers&quot; recruitment started in December
      2013. As of December 2014 there have been 55 participants enrolled, 18 were determined to be
      ineligible, 3 were discharged due to expected side effects (nausea and/or vomiting), 20
      completed with recruitment continuing. (December 2014)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2014</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">July 11, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Change on Items of the Drug Effects Questionnaire (DEQ)</measure>
    <time_frame>up to 55 minutes post-infusion</time_frame>
    <description>The peak change in the intensity of subjective effects as measured by the DEQ will be measured after each intravenous infusion.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Tobacco flavor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tobacco Flavor + IV saline, Tobacco Flavor + IV nicotine (0.25 mg/70kg), Tobacco Flavor + IV nicotine (0.5 mg/70kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose menthol + IV saline, Low dose menthol + IV nicotine (0.25 mg/70kg), Low dose menthol + IV nicotine (0.5 mg/70kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose menthol + IV saline, High dose menthol + IV nicotine (0.25 mg/70kg), High dose menthol + IV nicotine (0.5 mg/70kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV nicotine</intervention_name>
    <description>Subjects in each arm will receive three infusions in a fixed order one hour apart. The first infusion will be saline, the second infusion will be nicotine (.25 mg / 70kg) and the third infusion will be nicotine (0.5 mg / 70 kg).</description>
    <arm_group_label>Tobacco flavor</arm_group_label>
    <arm_group_label>Low dose menthol</arm_group_label>
    <arm_group_label>High dose menthol</arm_group_label>
    <other_name>nicotine, liquid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobacco Flavor</intervention_name>
    <description>A popular 'Burly' tobacco flavor used in e-cigarettes will be used as the placebo comparator.</description>
    <arm_group_label>Tobacco flavor</arm_group_label>
    <other_name>Burly American e-liquids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Menthol</intervention_name>
    <description>A low dose of menthol will be added to the tobacco flavor.</description>
    <arm_group_label>Low dose menthol</arm_group_label>
    <other_name>menthol, american e-liquid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Menthol</intervention_name>
    <description>A higher dose of menthol added to tobacco flavor will be an active intervention.</description>
    <arm_group_label>High dose menthol</arm_group_label>
    <other_name>menthol, american e-liquid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male smokers, aged 18 to 30 years;

          -  History of smoking for the past 12 months, at least one cigarette per day; smoking
             status is verified with urinary cotinine levels above 10 ng/ml;

          -  Not seeking treatment for nicotine dependence at the time of study entry;

          -  In good health as verified by medical history, screening examination, and screening
             laboratory tests;

          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and
             using acceptable birth control methods.

        Exclusion Criteria:

          -  History of major medical illnesses that the physician investigator deems as
             contraindicated for the patient to be in the study

          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics);

          -  A psychiatric diagnosis and / or treatment for Axis I disorders including major
             depression, bipolar affective disorder, schizophrenia or panic disorder in the past
             month

          -  Abuse of alcohol or any other recreational or prescription drugs in the past 30 days.

          -  Any allergy to propylene glycol or menthol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut VA Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Health Care System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Director of VA New England Mental Illness Research, Education and Clinical Center</investigator_title>
  </responsible_party>
  <keyword>menthol, electronic cigarette, nicotine, smoking, tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
